Antiretroviral News and Research

RSS

AIDS Healthcare Foundation blasts GlaxoSmithKline print advertisements that promote fear of HIV treatment

AIDS Healthcare Foundation (AHF) is blasting British multi-national drug giant GlaxoSmithKline (GSK) for a recent series of direct-to-consumer print advertisements that, under the guise of patient education, capitalize on patients' fears of HIV treatment.

25 Aug 2008

Computer modeling technology helps HIV treatment in developing nations

In the past 10 years, the global campaign to expand treatment for millions of people with AIDS living in resource-limited countries, especially in sub-Saharan Africa, has gained substantial commitments in public and private financing, and has made major strides in making treatment available to those who need it.

24 Aug 2008

About 1% of HIV-positive people worldwide have been tested for tuberculosis

Only 1% of people living with HIV/AIDS worldwide have been screened for tuberculosis, according to a report recently released by the coalition Advocacy To Control TB Internationally, or ACTION, Reuters reports.

13 Aug 2008

FDA approves Gilead's antiretroviral Viread for hepatitis B

Gilead Sciences on Monday announced that it has received FDA approval to market its antiretroviral drug Viread as a hepatitis B treatment, the AP/International Herald Tribune reports (AP/International Herald Tribune, 8/12).

13 Aug 2008

Rare case explains why some infected with HIV remain symptom free without antiretroviral drugs

AIDS experts at Johns Hopkins say they have compelling evidence that some people with HIV who for years and even decades show extremely low levels of the virus in their blood never progress to full-blown AIDS and remain symptom free even without treatment, probably do so because of the strength of their immune systems, not any defects in the strain of HIV that infected them in the first place.

12 Aug 2008

Children with HIV in poor countries more adherent to treatment than children in rich countries

Researchers from the Indiana University School of Medicine, the Regenstrief Institute and Moi University School of Medicine are the first to report that adherence to antiretroviral therapy (ART) to fight human immunodeficiency virus (HIV) in children who live in low income countries is as high as or higher than adherence by children living in high income countries.

11 Aug 2008

Technological crystal ball boosts AIDS survival

A cure for the virus that causes AIDS may still be beyond our grasp, but European researchers have developed a predictive software system for HIV that could help extend the lives of victims of the killer disease.

11 Aug 2008

RNAi used to dramatically suppress HIV infection in an organism

Hopes languished last September when a promising candidate HIV vaccine failed to work. Despite this setback, many researchers still believe immunization is possible, and a new study suggests they're correct-at least at the cellular level.

10 Aug 2008

Highly active antiretroviral therapy (HAART) equally effective in patients with or without history of injection drug use

Highly active antiretroviral therapy (HAART) has been extremely effective at slowing the progression of HIV infection to AIDS as well as extending the lives and improving the quality of life for those with HIV. However, some doctors have been reluctant to prescribe HAART to HIV-infected injection drug users because of concern that they may not fully benefit from the therapy.

6 Aug 2008

Experts say male circumcision the key to beating AIDS

Experts say while no cure or vaccine for AIDS exists male circumcision could be the key to driving the epidemic into a declining state and closer to extinction.

5 Aug 2008

Bionor Immuno trials new innovative therapeutic immunization designed to help existing HIV and AIDS patients

Bionor Immuno today announced that it has advanced its efforts to develop the first HIV therapeutic immunization with the dosing of patients in a global Phase 2b clinical trial of the company's lead candidate (Vacc-4x).

4 Aug 2008

Targeted action on HIV and tuberculosis needed to reach drug users

Health and criminal justice authorities need to provide targeted services to drug users, especially those who inject drugs, to prevent and treat tuberculosis (TB) and HIV. TB is a major cause of death for people living with HIV, but drug users who are HIV-positive face stigma, discrimination and barriers to accessing life-saving treatments.

4 Aug 2008

HIV in Kenya - 7.8% increase in 2007

HIV prevalence in Kenya increased to 7.8% in 2007, a slight increase from the 6.7% prevalence recorded in 2003, according to a survey released by the government on Tuesday, the Associated Press reports. According to the Associated Press, the increase in the percentage of the population living with HIV likely is because of wider access to antiretroviral drugs.

3 Aug 2008

HIV/AIDS advocates protest stigma, discrimination ahead of AIDS conference

HIV/AIDS advocates in Mexico City have begun protesting the problems of stigma, discrimination and a lack of access to antiretroviral drugs in Latin America ahead of next week's XVII International AIDS Conference in Mexico City, Agence France-Presse reports (Rosenthal, Agence France-Presse, 7/29).

3 Aug 2008

Eliminating funds for HIV/AIDS vaccine research, shifting funds to treatment 'dangerous sentiment,' opinion piece says

The call to eliminate all funding for HIV/AIDS vaccine research and prevention programs and "shifting" those funds to the expansion of HIV/AIDS treatment is a "dangerous sentiment" that is "sweeping over the AIDS establishment," Laurie Garrett, a senior fellow for global health at the Council on Foreign Relations, writes in an International Herald Tribune opinion piece.

3 Aug 2008

Abbott Labs agrees to settle lawsuit over antiretroviral Norvir pricing

Abbott Laboratories on Wednesday agreed to pay between $10 million and $27.5 million to settle an antitrust lawsuit filed by HIV/AIDS advocates and other drug companies over an increase in the price of the company's antiretroviral drug Norvir, the AP/International Herald Tribune reports (AP/International Herald Tribune, 7/31).

3 Aug 2008

Certain HIV treatment less effective when used with rifampicin-based anti-tuberculosis therapy

Patients receiving rifampicin-based anti-tuberculosis therapy are more likely to experience virological failure when starting nevirapine-based antiretroviral therapy, an HIV treatment that is widely used in developing countries because of lower cost, than when starting efavirenz-based antiretroviral therapy, according to a study in the August 6 issue of JAMA, a theme issue on HIV/AIDS.

3 Aug 2008

Growth hormone reduces abdominal fat, cardiovascular risk in HIV patients on antiviral therapy

Low-dose growth hormone treatment reduced abdominal fat deposits and improved blood pressure and triglyceride levels in a group of patients with HIV lipodystrophy, a condition involving the redistribution of fat and other metabolic changes in patients receiving combination drug therapy for HIV infection.

3 Aug 2008

Update of treatment guidelines for HIV infection recommended by experts

An evaluation of the latest information on the treatment of the adult human immunodeficiency virus (HIV) has led an international panel of experts to update the guidelines and recommendations for antiretroviral treatment of HIV.

3 Aug 2008

Merck announces significant price cuts on two of its AIDS drugs, Stocrin and Isentress

As more than 20,000 people from around the world gather this weekend for the start of the XVII International AIDS Conference in Mexico City, AIDS Healthcare Foundation (AHF) the US-based NGO which provides HIV/AIDS medical care and/or services to more than 79,000 individuals in 20 countries worldwide-including at four free treatment clinics in Mexico-commended Merck & Company (known as Merck, Sharp & Dohme in Mexico) over price cuts on two of its key AIDS drugs in Mexico which were announced yesterday before Sunday's opening of the AIDS conference.

3 Aug 2008

Antiretroviral News and Research

AIDS Healthcare Foundation blasts GlaxoSmithKline print advertisements that promote fear of HIV treatment

Computer modeling technology helps HIV treatment in developing nations

About 1% of HIV-positive people worldwide have been tested for tuberculosis

FDA approves Gilead's antiretroviral Viread for hepatitis B

Rare case explains why some infected with HIV remain symptom free without antiretroviral drugs

Children with HIV in poor countries more adherent to treatment than children in rich countries

Technological crystal ball boosts AIDS survival

RNAi used to dramatically suppress HIV infection in an organism

Highly active antiretroviral therapy (HAART) equally effective in patients with or without history of injection drug use

Experts say male circumcision the key to beating AIDS

Bionor Immuno trials new innovative therapeutic immunization designed to help existing HIV and AIDS patients

Targeted action on HIV and tuberculosis needed to reach drug users

HIV in Kenya - 7.8% increase in 2007

HIV/AIDS advocates protest stigma, discrimination ahead of AIDS conference

Eliminating funds for HIV/AIDS vaccine research, shifting funds to treatment 'dangerous sentiment,' opinion piece says

Abbott Labs agrees to settle lawsuit over antiretroviral Norvir pricing

Certain HIV treatment less effective when used with rifampicin-based anti-tuberculosis therapy

Growth hormone reduces abdominal fat, cardiovascular risk in HIV patients on antiviral therapy

Update of treatment guidelines for HIV infection recommended by experts

Merck announces significant price cuts on two of its AIDS drugs, Stocrin and Isentress

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News